The multi-dose randomized Phase 2 study enrolled approximately 52 patients in clinical sites in the US, Canada, Jamaica, Egypt and Lebanon.
The study aims to investigate the safety and tolerability of HQK-1001.
HQK-1001 belongs to a class of compounds originally discovered at Boston University School of Medicine.